Sitravatinib Withdrawn Phase 3 Trials for Hepatocellular Carcinoma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT05564338Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma